Zimmer Biomet Holdings (ZBH) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The OsseoFit Stemless Shoulder System (Anatomic) Post-Market Clinical Follow-up Study (NCT07421245) will track real-world use of Zimmer Biomet’s new stemless shoulder implant in patients with shoulder arthritis and related disease. It aims to show how safe and effective the system is over time, and how it affects pain, function, and X-ray outcomes in everyday clinical practice.
The study reviews two versions of the device. These are the OsseoFit Stemless Inlay, which sits partly within the bone, and the OsseoFit Stemless Onlay, which rests on top of the prepared bone surface.
The trial is observational and prospective, meaning surgeons use the devices as part of routine care and patients are then followed over time. There is no random assignment or placebo group, so the focus is on tracking outcomes in a real-world cohort rather than comparing different treatments head to head.
The study was first submitted on Feb. 13, 2026, and is currently listed as not yet recruiting, signaling early-stage planning. The last update on Feb. 18, 2026, confirms that the design and setup have been recently reviewed, but primary and final completion dates have not yet been posted.
For investors, this update flags Zimmer Biomet’s push deeper into stemless shoulder implants, a niche with rising demand as surgeons look for bone-preserving options. Positive long-term data could support higher adoption, strengthen ZBH’s position versus rivals in shoulder reconstruction, and over time help sentiment and valuation if the products deliver durable, low-complication outcomes.
The study is not yet recruiting but has been recently updated, and further details are available on the ClinicalTrials portal.